Clinical trials: Primary-progressive Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
Imaging of Intracerebral Inflammation in MS
In this study we plan to image the compartmentalized inflammation in MS using molecular imaging by positron emission tomography (PET) with a very highly resolutive camera.
- Conditions
- Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive
- Trial name
- INFLASEP (NCT02305264)
- Testing
- 18F-DPA-714 and 18F-FDG
- Where
- 2 sites in France
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
MS-ResearchBiomarkerS
This study is being conducted to investigate risk factors for disability progression in Multiple Sclerosis and related disorders (MSRD).
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
- Trial name
- MS-ReBS (NCT05204459)
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Cedars-Sinai Medical Center
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive
An Observational Biomarker Study in Multiple Sclerosis (MS) Patients
All males and females between 18-70 years of age regardless of their race and ethnicity with a confirmed diagnosis of Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), and Relapse…
- Conditions
- Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
- Trial name
- NCT05663853
- Where
- 4 sites in United States
- Volunteers
- 137 people
- Sponsor
- LAPIX Therapeutics Inc.
Primary Progressive Multiple Sclerosis
Serial Collection of Primary Progressive Multiple Sclerosis Participants in the MURDOCK Study
The goal of this study is to enroll 100 participants with Primary Progressive Multiple Sclerosis (PPMS) that have joined the MURDOCK Study Horizon 1.5 (Duke IRB Pro00011196) and the Multiple Sclerosis cohort (Duke IRB…
- Trial name
- NCT01776060
- Testing
- generation of 'omic markers of disease progression
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Duke University
Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
The Effects of In-phase Bilateral Exercise in People with Progressive Multiple Sclerosis
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system. MS, typical presents with progression of clinical symptoms which mainly include motor and cognitive impairment, as well as…
- Trial name
- NCT06436131
- Testing
- In-phase Bilateral Exercise, Conservative exercises
- Where
- Cyprus
- Volunteers
- 20 people
- Sponsor
- Cyprus University of Technology
Multiple Sclerosis
Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
The primary objective of this expanded access program is to provide ocrelizumab as treatment for eligible participants with primary progressive multiple sclerosis (PPMS) before it is commercially available in the United States…
- Trial name
- NCT02807285
- Testing
- Ocrelizumab
- Where
- 56 sites in United States
- Sponsor
- Genentech, Inc.
Migraine, Headache
RELAXaHEAD for Headache Patients (Phase II)
The goal of this research is to assess the utility of smartphone-based progressive muscle relaxation (PMR) for the treatment of migraine and sleep.
- Conditions
- Migraine, Headache, Multiple Sclerosis, Insomnia
- Trial name
- NCT05466682
- Testing
- Smartphone-Based Progressive Muscle Relaxation Therapy (PMR), Monitored Usual Care (MUC)
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- NYU Langone Health
Primary Progressive Multiple Sclerosis, Multiple Sclerosis, Secondary Progressive
Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS
The purpose of this study is to compare the efficacy and safety of andrographolide 140 mg administered twice a day orally versus a placebo as a modifying treatment of the disease in patients with the progressive forms of Multiple…
- Trial name
- NCT02273635
- Testing
- Andrographolides
- Where
- Chile
- Volunteers
- 68 people
- Sponsor
- Innobioscience SpA
Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis
The main purpose of this study is to evaluate the efficacy of ocrelizumab in participants with relapsing multiple sclerosis (RMS) and to characterize the ocrelizumab pharmacodynamic (PD) profile in Chinese participants with…
- Trial name
- NCT07483450
- Testing
- Ocrelizumab
- Where
- 17 sites in China
- Volunteers
- 60 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis
Phase Ib/II Study of SYS6020 in Relapsing/Refractory Multiple Sclerosis
This trial is an investigator-initiated, single-arm, open-label Phase Ib/II study to observe the safety, tolerability, PK/PD characteristics, immunogenicity, and the efficacy of SYS6020 injection in participants with…
- Trial name
- NCT07756268
- Testing
- SYS6020 injection
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Tongji Hospital
Multiple Sclerosis
Assessing the Role of Mitochondrial Dysfunction in Primary Progressive Multiple Sclerosis
The purpose of this project is to study genetic determinants of mitochondrial impairment in primary progressive multiple sclerosis.
- Trial name
- NCT06025903
- Where
- 2 sites in Italy
- Volunteers
- 140 people
- Sponsor
- IRCCS San Raffaele
ALS, Amyotrophic Lateral Sclerosis
NYSCF Scientific Discovery Biobank
The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood cells) to make stem cells and other types of cells…
- Conditions
- ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset
- Trial name
- NCT06203106
- Testing
- Biological Sample Collection
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- New York Stem Cell Foundation Research Institute
Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Relapsing-Remitting
Exercise Effects in Multiple Sclerosis
A growing body of work suggests that regular exercise can support symptom management and improve physical function for people living with multiple sclerosis (MS).
- Conditions
- Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Chronic Progressive
- Trial name
- NCT05496881
- Testing
- Exercise Group 1, Exercise Group 2, Exercise Group 3
- Where
- Canada
- Volunteers
- 69 people
- Sponsor
- University of Regina
Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis
PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF
This is a study of PIPE-791, an investigational study drug to treat progressive multiple sclerosis (MS) and idiopathic pulmonary fibrosis (IPF).
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis, Multiple Sclerosis, Multiple Sclerosis, MS
- Trial name
- NCT06683612
- Testing
- PIPE-791
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Contineum Therapeutics
Multiple Sclerosis, Progressive Multiple Sclerosis
Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple Sclerosis
This is a three-week crossover study that will compare how the body absorbs and tolerates two different forms of lipoic acid: R form and racemic form.
- Conditions
- Multiple Sclerosis, Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
- Trial name
- NCT03493841
- Testing
- Alpha Lipoic Acid
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Rebecca Spain
Sclerosis, Multiple, Autoimmune Diseases of the Nervous System
Safety and Efficacy of Melatonin in Patients With Multiple Progressive Primary Sclerosis
Phase I / II randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of melatonin administration combined with ocrelizumab in patients with Progressive Multiple Primary Sclerosis.
- Conditions
- Sclerosis, Multiple, Autoimmune Diseases of the Nervous System, Nervous System Diseases, Autoimmune Diseases
- Trial name
- NCT03540485
- Testing
- Melatonin
- Where
- 3 sites in Spain
- Volunteers
- 25 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Multiple Sclerosis
Sunphenon in Progressive Forms of Multiple Sclerosis
The investigators hypothesize that an oral Sunphenon EGCg (Epigallocatechin-Gallat, EGCG) treatment is - due to its antiinflamatoric and neuroprotective potence - significantly more effective than an oral placebo treatment…
- Trial name
- SUPREMES (NCT00799890)
- Testing
- Sunphenon EGCG
- Where
- Germany
- Volunteers
- 61 people
- Sponsor
- Friedemann Paul
Multiple Sclerosis, Primary Progressive Multiple Sclerosis (PPMS)
IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis
This is an open label, Phase 1b, multiple ascending dose, and dose-expansion study of IDP-023 administered in combination with interleukin-2 (IL-2) and ocrelizumab to evaluate the safety, tolerability, and biologic activity on…
- Conditions
- Multiple Sclerosis, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), Non-Active Secondary Progressive Multiple Sclerosis
- Trial name
- NCT06677710
- Testing
- IDP-023, Ocrelizumab, Interleukin-2
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- Indapta Therapeutics, INC.
Multiple Sclerosis
Hydroxyurea in Primary Progressive Multiple Sclerosis
The pathogenesis of MS remain elusive, however some studies have linked the disease with infection by Epstein-Barr virus; therefore the use of drugs with immunosuppressive or immunomodulating action alone may be less suitable for…
- Trial name
- NCT01103583
- Testing
- Hydroxyurea
- Where
- 2 sites in Italy
- Volunteers
- 33 people
- Sponsor
- S. Andrea Hospital
Multiple Sclerosis, Primary Progressive
A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
This randomized, parallel group, double-blind, placebo controlled study will evaluate the efficacy and safety of ocrelizumab in participants with primary progressive multiple sclerosis.
- Trial name
- NCT01194570
- Testing
- Ocrelizumab
- Where
- 184 sites in United States, Australia and 27 more
- Volunteers
- 735 people
- Sponsor
- Hoffmann-La Roche